Does the treatment of cryptogenic fibrosing alveolitis influence prognosis?

Respiratory Medicine

Volumn 90, Issue 3, 1996, Pages 127-130

  Egan, J J ^a   Woodcock, A A ^a  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; PENICILLAMINE; PENTETATE TECHNETIUM TC 99M; PREDNISOLONE;

CLINICAL TRIAL; DISEASE COURSE; FIBROSING ALVEOLITIS; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG BIOPSY; LUNG LAVAGE; NEPHROTIC SYNDROME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; STEROID THERAPY; TREATMENT OUTCOME;

EID: 0029919750     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(96)90153-5     Document Type: Review

References (26)

1. Johnston IDA, Gomm SA, Kalra S, Woodcock AA, Evans CC, Hind CRK. The management of cryptogenic flbrosing alveolitis in three regions of the United Kingdom. Eur Respir J 1993; 6: 891-893.
2. Wells AU, Du Bois RM. Predictor of disease progression in idiopathic pulmonary fibrosis. Eur Respir J 1994; 7: 637-639.
3. Raghu G. Interstitial lung disease: a diagnostic approach. Am J Respir Crit Care Med 1995; 151: 909-914.
4. Stack BHR, Choo-Kang YFJ, Heard BE. The prognosis of cryptogenic fibrosing alveolitis. Thorax 1972; 27: 535-542.
5. Turner-Warwick M, Burrows B, Johnson A. Crpytogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980; 35: 171-180.
6. Scadding JG. Diffuse interstitial fibrosis of the lung. BMJ 1960; 1: 443-450.
7. Carrington CB, Gaensler EA, Coutu RE, Fitzerald MX, Gupta RG. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978; 298: 801-809.
8. McDonald JA. Idiopathic pulmonary fibrosis, a paradigm for lung injury and repair. Chest 1991; 99: 87S-93S.
9. Cherniack RM, Colby TV, Flint A et al. Correlation of structure and function in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995; 151: 1180-1188.
10. Dayton CS, Schwartz DA, Helmers RA et al. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy, Implications for future studies. Chest 1993; 103: 69-73.
11. Miller MR, Pincock AC. Predicted values: how should we use them? Thorax 1988; 43: 265-267.
12. Agusti C, Xaubet A, Agusti AGN, Roca J, Ramirez J, Rodriguez-Rosin R. Clinical and functional assessment of patients with idiopathic pulmonary fibrosis: results of a 3 year follow up. Eur Respir J 1994; 7: 643-650.
13. 99mTc-DTPA predicts the clinical course of fibrosing alveolitis. Eur Resp J 1993; 6: 797-802.
14. Wells AU, Hansell DM, Rubens MB, Cullinan P, Black CM, DuBois RM. The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am Rev Respir Dis 1993; 148: 1076-1082.
15. Kuhn C, Boldt J King TE, Crouch E, Varito T, McDonald JA. An immunohistochemical study of architectural remodelling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis 1989; 140: 1693-1703.
16. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: response to corticosteroid treatment and its effect on survival. Thorax 1989; 35: 593-399.
17. Johnson MA, Kwan S, Snell NJC, Nunn AJ, Darbyshire JH, Turner-Warwick M. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis Thorax 1989; 44: 280-288.
18. Raghu G, Depaso WJ, Cain K et al. Azathioprine combined with prednisolone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomised, placebo controlled clinical trial. Am Rev Respir Dis 1991; 144: 291-296.
19. Moolman JA, Bardin PG, Rossouw DJ, Joubert JR. Cyclosporin as a treatment for interstitial lung disease of unknown aetiology. Thorax 1991; 46: 592-595.
20. Alton EWF, Johnson M, Turner-Warwick M. Advanced cryptogenic fibrosing alveolitis: preliminary report on treatment with cyclosporin A. Respir Med 1989; 83: 277-279.
21. Rennard SI, Bitterman PB, Ozaki T, Rom WN, Crystal RG. Colchicine suppresses the release of fibroblast growth factors from alveolar macrophages in vitro. Am Rev Respir Dis 1988; 137: 181-185.
22. Peters SG, McDougall JC, Douglas WW, Coles DT, DeRemeee RA. Colchicine in the treatment of pulmonary fibrosis. Chest 1993; 103: 101-104.
23. Meier-Sydow J, Rust M, Kronenberger H, Krempel S. Survival of patients with idiopathic pulmonary fibrosis following treatment with azathioprine, d-penicillamine or prednisoline ten year follow-up. Chest 1990; 94: 18S.
24. Kelley J. Cytokines of the lung. Am Rev Respir Dis 1990; 141: 765-788.
25. Lacronique JG, Rennard SI, Bitterman PB, Ozaki T, Crystal RG. Alveolar macrophages in idiopathic pulmonary fibrosis have glucocorticoid receptors, but glucocorticoid therapy does not supress alveolar macrophage release of fibronectin and alveolar macrophage derived growth factor. Am Rev Respir Dis 1984; 130: 450-456.
26. Hunninghake GW, Kalica AR. Approaches to treatment of pulmonary fibrosis. Am J Respir Crit Care Med 1995; 151: 915-918.